The analyst believes Hims & Hers is making the right strategic moves by acquiring Eucalyptus, which significantly expands its international market and subscriber base. This acquisition, combined with recent partnerships with major pharmaceutical companies, is expected to drive substantial revenue growth (potentially 40-50% later in 2026) and solidify its position as a healthcare aggregator, despite short-term margin compression and increased debt.
“I think all of this is the right strategic moves. ... If we do see a growth rate of 40 50% which we probably will later this year with eucalyptus now on board that is going to be a big deal for the stock.” — ▶ 10:00